CCM
CKPT

Chiron Capital Management’s Checkpoint Therapeutics CKPT Stock Holding History

Chiron Capital Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$5K – 143
2020
Q3 		$5K Buy
+200
New +$4.8K ﹤0.01% 359

Other funds holding CKPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Chiron Capital Management's CKPT Position: Q4 2020 in Review

Chiron Capital Management sold out of Checkpoint Therapeutics (CKPT) in Q4 2020, closing a stake of 200 shares — an estimated $5K sold.

Chiron Capital Management first reported a position in CKPT in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 62 funds tracked by Wall St. Rank hold CKPT as of Q4 2020.

  • Chiron Capital Management reported no remaining Checkpoint Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 200 Checkpoint Therapeutics shares in Q4 2020, an estimated $5K.
  • Chiron Capital Management first reported a position in Checkpoint Therapeutics in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Checkpoint Therapeutics position peaked at $5K in Q3 2020.
  • 62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.